Erythropoietin for Liver Transplant Rejection

Palo Alto (17 mi)

Overseen byJosh Levitsky, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Northwestern University

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.

Eligibility Criteria

This trial is for adults aged 18-74 who had a liver transplant over 2 years ago due to non-immune causes and are on stable immunosuppressive monotherapy. They must be able to consent and not have high hemoglobin levels, severe hypertension, end-stage renal disease, history of blood clots or heart issues, active cancer, allergies to erythropoietin or certain other substances.

Treatment Details

The study tests if Erythropoietin (EPO) can increase the number and effectiveness of Tregs in liver transplant recipients. It will compare the effects of EPO in patients treated with either tacrolimus or everolimus to find a better treatment strategy towards tolerance.

1Treatment groups

Experimental Treatment

Group I: EPO ArmExperimental Treatment1 Intervention